Avadel Pharmaceuticals (AVDL) Q2 2024 earnings summary

Executive summary

• LUMRYZ, the sole commercial product, marked its one-year launch anniversary with strong uptake, surpassing 1,900 patients on therapy as of June 30, 2024, and significant impact in the narcolepsy community.

• Net product revenue reached $41.5 million for Q2 2024 and $68.7 million for H1 2024, reflecting rapid commercial growth since launch.

• Net loss narrowed to $13.8 million for Q2 2024, a substantial improvement from $64.4 million in the prior year, with gross margin at 93.3%.

• LUMRYZ is expanding the oxybate market, attracting both switch and new-to-oxybate patients, and new prescribers.

• Ongoing litigation and regulatory matters, including patent disputes and an FDA decision for pediatric use expected by September 2024, remain key factors.

Financial highlights

• Q2 2024 net revenue was $41.5 million, with gross profit of $38.7 million and gross margin of 93.3%.

• Operating loss for Q2 2024 was $12.7 million, improved from $49.5 million in Q2 2023.

• GAAP operating expenses were $51.5 million, including a $5 million nonrecurring expense for ADR program termination.

• Cash, cash equivalents, and marketable securities totaled $71.4 million at quarter end.

• Net loss per diluted share was $0.14 for Q2 2024.

Outlook and guidance

• Recurring quarterly cash operating expenses are expected to be $40–$45 million for the rest of 2024.

• The company expects to achieve operating income in Q3 2024 and is comfortable with the full-year revenue consensus of $168 million.

• FDA decision on pediatric narcolepsy indication is expected in September 2024.

• Update on low/no sodium formulation is anticipated by year-end 2024.

• Cash and marketable securities, plus anticipated LUMRYZ sales, are expected to fund operations for at least the next 12 months.